ホーム » カタログRNA＆LNP製品 » eGFP mRNA (Cap1, 5-MOU)
EGFP MRNA (Cap1, 5-MOU)

Expression of eGFP mRNA (5-MOU) in A549 cells. The eGFP expression was measured 24 hours after transfection of mRNA by lipofectamine by plate reader. m1Ψ modified EGFP mRNA was utilized as a control.

eGFP mRNA (Cap1, 5-MOU)

This product is unavailable.
The eGFP mRNA expresses an enhanced green fluorescent protein (Ex: 488nm, Em: 507nm). This mRNA is capped with Cap1 structure with high capping efficiency. It has 100% substituted with 5’-Methoxyuridine for enhanced expression and reduced immunogenicity. The GenScript patented UTR is used in this mRNA. The mRNA has a 100A tail in its sequence, mimics a mature mRNA. EGFP mRNA is a commonly used fluorescence reporter sequence in mRNA therapeutics and delivery system development projects.
RP-A00008
Ask us a question
Description

The eGFP mRNA encodes an enhanced green fluorescent protein, originally derived from the jellyfish, Aequorea victoria. eGFP mRNA is widely used as a fluorescent reporter in mRNA-based research, especially in therapeutic development and delivery system validation. The expressed eGFP protein fluoresces green, with excitation at 488 nm and emission at 507 nm.  
 
This mRNA features: 
- A Cap 1 structure with high capping efficiency 
- 100% substitution with 5’-Methoxyuridine (5-MOU) for improved protein expression and reduced innate immune response 
- GenScript’s patented UTR to enhance translation 
- A 100A poly(A) tail to mimic natural mature mRNA 
 
This construct offers strong, reliable fluorescent signaling, making it ideal for transfection optimization, biodistribution studies, and LNP delivery validation.
Properties
Form Liquid
Concentration 1mg/mL
Full mRNA length 980nt  
Full mRNA Molecular Weight 324468
Storage buffer 1mM Sodium citrate, pH6.5
Storage condition Store at -20°C for short term (<3 months), store at -80°C for long term.

Quality Control Specifications
Appearance Clear and free of foreign particles
RNA Length Expected size band detected
RNA Content Target ± 5%
Integrity ≥ 75%
OD260/OD280 1.70 ~ 2.30
Capping Efficiency ≥ 90%
Endotoxin < 10 EU/mg
pH Target ± 0.5

Applications
Transfect 0.1-0.2 µg of mRNA with 0.5 µL of Lipofectamine™ 2000 (or equivalent reagent) per well in a 96-well plate, following the manufacturer’s protocol. Analyze the expression 16-48 hours post-transfection using a plate reader, flow cytometer, fluorescence microscope, or confocal microscope. For equipment settings, we recommend: 485 nm excitation, 535 nm emission.

Examples
  • EGFP MRNA (Cap1, 5-MOU)
    • EGFP MRNA (Cap1, 5-MOU)

    Expression of eGFP mRNA (5-MOU) in A549 cells. The eGFP expression was measured 24 hours after transfection of mRNA by lipofectamine by plate reader. m1Ψ modified EGFP mRNA was utilized as a control.


For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.